Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31350708 | 0.78 | HPGD (0.60) | FNTAFNTB | |
| SCHEMBL3263639 | 0.78 | DRD1 (0.46) | DRD1DRD2DRD5FNTAFNTB | |
| SCHEMBL9063252 | 0.77 | NPC1 (0.49) | FNTAFNTB | |
| SCHEMBL5267462 | 0.76 | CACNA1G (0.77) | CACNA1G | |
| SCHEMBL13503895 | 0.76 | PRCP (0.54) | DRD1DRD2DRD5 | |
| SCHEMBL7682324 | 0.76 | ALDH1A1 (0.53) | NPSR1 | |
| SCHEMBL31350745 | 0.76 | FNTA (0.56) | FNTAFNTB | |
| SCHEMBL2946237 | 0.75 | DRD1 (0.65) | DRD1DRD2DRD5 | |
| SCHEMBL14079264 | 0.75 | NOTUM (0.47) | NPSR1LMNACACNA1G | |
| SCHEMBL31350903 | 0.75 | FNTA (0.46) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | US | disclosed |
| US-7868007-B2 | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | NPSR1 329/4885LMNA 2067/4885CACNA1G 159/4885 |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | NPSR1 329/4885LMNA 2067/4885CACNA1G 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.